Tocilizumab modulates the activity of the classical and alternative complement pathways in rheumatoid arthritis patients

Tocilizumab modulates the activity of the classical and alternative complement pathways in rheumatoid arthritis patients

BackgroundTocilizumab (TCZ) is a monoclonal antibody that neutralizes interleukin (IL)-6 and is indicated for diseases characterized by markedly elevated inflammatory markers, such as rheumatoid arthritis (RA). The complement system has been implicated in the etiopathogenesis of RA.ObjectiveTo evalu...

Full description

Bibliographic Details
Main Authors: Iván Ferraz-Amaro, Sergio Santos-Concepción, Javier Castro-Hernández, Maria Vanesa Hernández-Hernández, Beatriz Tejera Segura, Cristina Luna, Esmeralda Delgado-Frias, Federico Díaz-González
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Immunology
Subjects:
tocilizumab
rheumatoid arthritis
disease activity
classical complement system activity
alternative complement system activity
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1486588/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1486588/full

Similar Items